Life Science Investing Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering 17 October
Life Science Investing Praxis Precision Medicines, Inc. Announces Proposed Public Offering 16 October
Life Science Investing Praxis Precision Medicines Announces Positive Topline Results from Two Pivotal Phase 3 Studies of Ulixacaltamide HCl in the Essential3 Program for Essential Tremor 16 October
